Shinpoong Pharmaceutical Co.,Ltd

KOSE:A019170 Stock Report

Market Cap: ₩577.5b

Shinpoong PharmaceuticalLtd Valuation

Is A019170 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A019170 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A019170's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A019170's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A019170?

Key metric: As A019170 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A019170. This is calculated by dividing A019170's market cap by their current revenue.
What is A019170's PS Ratio?
PS Ratio2.6x
Sales₩215.44b
Market Cap₩577.52b

Price to Sales Ratio vs Peers

How does A019170's PS Ratio compare to its peers?

The above table shows the PS ratio for A019170 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
A170900 Dong-A ST
0.8x6.2%₩554.0b
A053030 BINEX
4x28.9%₩517.8b
A001060 JW Pharmaceutical
0.8x10.3%₩591.4b
A000640 Dong-A Socio Holdings
0.5x5.7%₩674.5b
A019170 Shinpoong PharmaceuticalLtd
2.6xn/a₩577.5b

Price-To-Sales vs Peers: A019170 is expensive based on its Price-To-Sales Ratio (2.6x) compared to the peer average (1.5x).

Price to Sales Ratio vs Industry

How does A019170's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$158.67m
A002620 Jeil Pharma Holdings
0.2xn/aUS$92.36m
A000230 Ildong Holdings
0.1xn/aUS$57.08m
No more companies available in this PS range
A019170 2.6xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A019170 is expensive based on its Price-To-Sales Ratio (2.6x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A019170's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A019170 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A019170's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩271,000.00

7D

-1.8%

1Y

76.5%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

7D

-4.8%

1Y

n/a

Dong-A ST

₩554.0b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩61,700.00

7D

-9.7%

1Y

7.9%